中國生物科技服務(08037.HK)：上海隆耀獲戰略注資9800萬元 以推進CAR-T細胞療法及集團其他主要業務增長機會
格隆匯12月9日丨中國生物科技服務(08037.HK)發佈公吿，於2023年12月8日，公司、上海隆耀(公司間接非全資附屬公司)及投資者宜興環科園產發股權投資合夥企業(有限合夥)訂立注資協議，據此(i)投資者同意作出金額人民幣4800萬元的注資，其中人民幣992,670元用於認購上海隆耀經擴大註冊股本的5.35%股本權益，及人民幣4701萬元計入上海隆耀的股本儲備，(ii)公司同意(透過將於中國成立的全資附屬公司)作出金額人民幣4996萬元的注資，其中人民幣103萬元用於認購上海隆耀經擴大註冊股本的5.57%股本權益，及人民幣4893萬元計入上海隆耀的股本儲備。
(iii)授予投資者認沽期權，倘若發生任何贖回事件，投資者有權要求上海隆耀以認沽價格回購，或(倘若上海隆耀未能回購)要求公司以認沽價格收購投資者於上海隆耀的全部或部分股權，及(iv)授予公司認購期權，公司可於2024年12月31日或之前酌情行使，據此公司可收購投資者於上海隆耀的全部或部分股權。
注資完成後，集團於上海隆耀的即時實際股本權益將由約68.13%減少約1.87%至66.26%。上海隆耀仍將為公司的附屬公司，其業績、資產及負債將繼續併入公司的綜合財務報表。
上海隆耀為一間於2013年9月16日於中國成立的有限公司，主要從事CAR-T療法的研發業務。
CAR-T細胞療法在治療若干類型癌症方面證明具有臨牀療效及安全。公司相信上海隆耀的CAR-T細胞免疫治療技術在臨牀癌症治療方面具有巨大潛力。各方協定，上海隆耀將以注資的全部所得款項用於改造GMP生產基地和採購儀器及設備、CD20-CART-OX40的臨牀研究以及其他產品項目的研發。注資將推進公司把握CAR-T細胞療法及集團其他主要業務增長機會的計劃。
此外，上海隆耀的現有股東擬於2027年12月31日之前實現上海隆耀於證券交易所成功上市。然而，此仍為現時的初步計劃，尚未就成功上市提出具體建議或確定具體時間。董事認為，就向上海隆耀及其附屬公司提供股權融資以支持其發展及促進未來融資活動而言，引入投資者將對集團有利。倘若上海隆耀未能如期上市，認沽期權亦為投資者提供一個合理的選擇權以撤回其權益。鑑於上海隆耀作為中國私營公司，其股本權益交易並無公開市場，董事認為該退出選擇權為上市前投資的常見市場慣例。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
